The urgency underlying the agenda was captured early by Chyke Doubeni, MD, MPH, Chief Health Equity Officer at The Ohio State University Wexner Medical Center. Established prevention and screening strategies, he told attendees, have the power to eliminate nearly half of all cancer deaths, yet barriers continue to prevent many Americans from accessing these opportunities. Doubeni warned that new screening technologies carry transformative potential for cancer detection, but that their value will not be realized equitably unless the fragmented delivery processes that risk deepening existing disparities are addressed. His framing set the tone for two days of discussion in which scientific optimism was repeatedly tempered by structural realism: the tools exist, the evidence exists, and the remaining challenge is one of delivery, coverage, and trust.

That tension between knowledge and access was echoed by Darcie Green, Executive Director of Latinas Contra Cancer, who argued that the field knows more than it ever has about preventing cancer, lowering risk, and finding disease earlier, but that too much distance remains between what is known and what people can actually access and benefit from. Green called for closing that distance by bringing excellent care and patient navigation within reach and by engaging patients and communities in shaping the systems meant to serve them. Jody Hoyos, MHA, Chief Executive Officer of the Prevent Cancer Foundation, described how rapidly the paradigm is shifting: cancer prevention is no longer only about avoiding risk, she said, but about using better science, smarter screening, and earlier detection to find cancer before it becomes life-threatening. She added a practical caveat that resonated through the meeting—patients are demanding less invasive and more accessible options, and uptake will only improve if the field responds to that demand.

Day one of the summit focused on broad, population-level strategies, spanning public health infrastructure, tobacco cessation, vaccines against cancer-causing infections, emerging blood-based tests, and artificial intelligence-driven efficiencies in screening programs. Speakers emphasized that these interventions, deployed at scale, represent the clearest near-term opportunity to bend the cancer mortality curve. Mishellene McKinney, MHA, RN, OCN, Vice President of Clinical Programs at Kaiser Foundation Health Plan and Hospitals, offered an integrated delivery perspective, explaining that value-based care models can proactively engage people in prevention and screening through personalized outreach and evidence-based approaches. As both health plan and care provider, Kaiser Permanente, she said, recognizes preventing cancer as a critical part of overall care and is committed to making screening more accessible, equitable, and effective for members and surrounding communities.

The second day shifted to system-level solutions for meeting individual screening needs, particularly among higher-risk populations. Discussions covered hereditary risk assessment, follow-up diagnostics after abnormal findings, out-of-pocket costs, and continuity of care across the full cancer journey. Lisa Schlager, Vice President of Public Policy for FORCE: Facing Our Risk of Cancer Empowered, stressed that cancer risk is not one-size-fits-all: age, family history, genetics, and environmental and lifestyle factors all shape an individual’s probability of disease. Screening and prevention strategies, she argued, should be tailored so patients receive the most appropriate care for their risk profile, and public policies must evolve so patients can access the right interventions at the right time—an approach she said would improve outcomes, save lives, and reduce healthcare costs simultaneously.

Continuity of care emerged as one of the summit’s most persistent themes. Brandon Leonard, MA, Vice President of Government Affairs at LUNGevity Foundation, identified the central systems challenge as ensuring that patients move seamlessly from initial screening through follow-up diagnostics, treatment, and survivorship care. From a policy standpoint, he called for eliminating access barriers by guaranteeing that screening and diagnostics are covered for all eligible patients without burdensome cost-sharing or utilization management requirements. Molly Guthrie of Susan G. Komen reinforced the point with a concrete legislative record: Komen’s Center for Public Policy has led the introduction of, and helped pass, dozens of state bills to remove barriers standing in the way of affordable, accessible breast imaging. Gaps remain, she cautioned, and laws must continue to evolve so that all patients can obtain the screening they need without financial burden—a goal requiring collective action at both state and federal levels.

Disparities in screening access and experience received pointed attention, including for communities often overlooked in mainstream cancer control conversations. Scout, PhD, Executive Director of The LGBTQIA+ Cancer Network, identified medical mistrust as one of the biggest screening barriers for LGBTQIA+ people, citing recent data showing that this barrier has grown notably worse for 75 percent of that population within the last 18 months. Simple, low-cost interventions—welcoming signage, inclusive badges, visible signals of affirmation—can counteract that mistrust, Scout argued, while medical offices that fail to take such steps actively perpetuate disparities. The observation underscored a recurring summit message: equity in cancer screening is built or lost in thousands of small, everyday clinical interactions, not only in federal legislation.

Genetic risk and the promise of precision prevention figured prominently as well. Tuya Pal, MD, a clinical geneticist at Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center, and Vice-Chair of the NCCN Guidelines Panel for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, emphasized that access after testing is what actually saves lives. People with inherited genes that elevate cancer risk have tremendous potential to benefit from screening, she noted, but it is not testing alone that improves outcomes—rather, it is accessing appropriate care based on the results. To reap the benefits of genetic testing, the field must ensure that all individuals can obtain recommended screening and preventive measures once a result is in hand. Her comments reframed the national conversation about expanding genetic testing, warning that testing capacity without downstream care is a hollow victory.

Speakers also grappled with how to translate accelerating scientific progress into practical, responsible care. Ernest Hawk, MD, MPH, Head of Cancer Prevention and Population Science at The University of Texas MD Anderson Cancer Center, acknowledged that the science of cancer prevention and screening has advanced remarkably, and that translating that evidence into clinical tools for risk assessment, evidence-based screening programs, and practice standards has already helped save countless lives. Looking ahead to innovations such as multicancer detection tests moving closer to clinical practice, he urged balance: enthusiasm for their potential must be weighed against careful consideration of potential harms, costs, and implications for population health, until rigorous evidence demonstrates meaningful improvements in outcomes. Elisa M. Rodriguez, PhD, MS, of Roswell Park Comprehensive Cancer Center, added a patient-centered dimension from her own experience delivering cancer risk information: people do not simply want a risk score or percentage, she said—they want actionable information on what they can do to help protect themselves from developing cancer.

The summit also featured remarks from NCCN’s Chief Medical Officer, Renuka Iyer, MD, and Chief Scientific Officer, Nancy L. Lewis, MD, MBS, FACP, with panels moderated by Clifford Goodman, PhD, a consultant in health care technology and policy, and a series of presentations showcasing effective screening and prevention strategies in action. Attendees could pick up copies of the free NCCN Guidelines for Patients on screening and prevention—covering breast cancer screening and diagnosis, colorectal screening, genetic testing, lung cancer screening, and prostate cancer screening—all available in English and Spanish at NCCN.org/patients through funding from the NCCN Foundation. The organization’s next convening, the annual Patient Advocacy Summit on December 3, 2026, also in Washington, D.C., will turn to advancing family-centered cancer care, examining gaps in government support, awareness of assistance programs, and caregiver information. For a field that can already prevent roughly half of cancer deaths with tools in hand, the summit’s collective message was clear: the next frontier is not discovery, but delivery.

Subject of Research: Cancer prevention and screening policy, equity, and access discussed at the NCCN Oncology Policy Summit

Article Title: Cancer prevention and screening takes center stage during DCSummit convened by NCCN

Article References: Cancer prevention and screening takes center stage during DCSummit convened by NCCN. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: NCCN, cancer prevention, cancer screening, health equity, National Cancer Institute, CDC, genetic testing, early detection, health policy, patient advocacy, multicancer detection tests, screening disparities

The authors build their case from a series of revealing examples drawn from British screening history. The UK National Screening Committee recommended against population-based prostate cancer screening, concluding that while screening prevented prostate cancer deaths, it also caused harm through overdiagnosis and overtreatment, leaving some men with urinary incontinence or erectile dysfunction. In reaching that conclusion, the committee made a value judgement about how to weigh extended life against morbidity — and, the authors note, it assumed without evidence that individual men would share its values. Meanwhile, when Wales extended the cervical screening interval for women aged 25 to 49 from three years to five in 2022, a scientifically defensible decision triggered a public outcry and a petition signed by more than a million people, prompting England to delay the same change until July 2025.

Bowel screening illustrates how resources quietly shape supposedly clinical thresholds. The faecal immunochemical test, or FIT, applies a binary cut-off to the amount of blood in a stool sample, and that cut-off ranges from 8.5 to 150 micrograms of haemoglobin per gram of faeces across programmes, largely to manage colonoscopy capacity. Historically, Wales used a threshold of 150, England 120 and Scotland 80 micrograms per gram — meaning a result deemed normal in England could have triggered a colonoscopy just across the Scottish border. The stakes of delay are also stark: randomised trials showed guaiac-based faecal occult blood testing reduced colorectal cancer mortality as early as 1996, yet England’s screening programme only completed roll-out in 2010. Screening now prevents roughly 2,000 colorectal cancer deaths annually in England; had it rolled out in 2000, the authors estimate some 20,000 premature deaths could have been averted.

To make sense of such cases, Sasieni and John adapt five principles for decision-making under uncertainty — proportionality, justice, autonomy, feasibility and adaptability — into a framework specifically for cancer screening. Their central claim is that policymakers suffer from an asymmetry of fear: they worry intensely about false-positive decisions, such as introducing a screening programme that turns out to do more harm than good, while largely ignoring false-negative decisions, in which beneficial programmes are delayed or withheld. Because committees periodically revisit recommendations, a cautious ‘not yet’ feels reversible and safe. But delay has consequences that can be quantified even without certainty. If prostate screening in men aged 50 to 65 reduces prostate cancer mortality by 25 percent over 15 years, a two-decade implementation delay could translate into around 20,000 avoidable deaths in the UK. Conversely, had multimodal ovarian cancer screening been introduced for women aged 50 to 74 before the definitive UKCTOCS trial results, roughly 7,000 women each year might have undergone unnecessary surgery. Both sides of the ledger can be estimated, the authors argue, and should be before decisions are made.

The principle of justice exposes another hidden cost of slowness: inequality. Wealthy and well-educated people frequently obtain screening privately long before public programmes roll out. In the United States, colonoscopy use is 50 percent higher in the wealthiest socioeconomic quintile than in the poorest. In England, prostate-specific antigen testing is 25 percent lower in the most deprived quintile — and metastatic prostate cancer rates there are 11 percent higher, while overall prostate cancer incidence is 19 percent lower, plausibly reflecting inequitable access to asymptomatic PSA testing. Justice also complicates the details: some researchers argue FIT referral thresholds should differ for women and men, but the right answer depends on which measure of equity one chooses to prioritise, a value judgement that should be made transparently. Even overdiagnosis falls unevenly — introducing prostate screening for men in their seventies would generate more overdiagnosis among the most deprived, whose shorter life expectancy means more of them die of other causes before screening could ever help.

Autonomy poses a deeper philosophical problem. Public health typically overrides individual preferences for the collective good, while clinical medicine demands informed consent. Screening sits awkwardly between: society seeks consent before screening anyone, yet takes a paternalistic stance on what screening is offered at all, rarely considering the ethics of denying screening to those who want it. The authors suggest a more democratic division of labour, inspired by the Dutch model: expert committees could summarise evidence and uncertainties without issuing recommendations, forcing elected politicians to make the value-laden choices explicitly. Where experts disagree, politicians should decide. They even sketch a personalised option for prostate screening — inviting men aged 50 to 69 for triennial PSA testing without encouraging participation, letting personal risk tolerance guide the decision, much as oncology patients weigh their own treatment choices.

Feasibility, the authors stress, already governs screening policy whether it is admitted or not. FIT thresholds and age ranges are set by colonoscopy capacity; MRI-based prostate screening would demand vast new infrastructure of scanners and staff; and in low- and middle-income countries, cervical screening is constrained by the lack of facilities to triage screen-positive women and treat precancerous lesions. Public opinion constrains policy too — hence the continued offering of cervical screening at age 25 to women vaccinated against HPV as adolescents, despite their extremely low cervical cancer risk and the likelihood that screening does them more harm than good. The authors argue the public is mature enough to understand these trade-offs, provided they are communicated honestly.

Adaptability may be the most urgent principle in an era of artificial intelligence and liquid biopsies. Traditional screening trials are ruinously expensive — the National Lung Cancer Screening Trial cost 256 million dollars in 2002, roughly 400 million today — and a binary framework of full national implementation or complete rejection leaves no pathway for pragmatic pilots that generate evidence while delivering benefit. Multicancer detection tests sharpen the dilemma: by the time one test’s clinical utility is fully evaluated, the technology will be outdated, and trial designs that test each cancer type separately would require randomising millions of people. The authors call for publicly funded pilots designed to fill evidence gaps, with implementation beginning in health-deprived regions to address injustice rather than widen it. They are candid about the risks of permissiveness — a pilot ovarian screening programme before 2021 would have harmed some healthy women with false positives — but insist those harms and benefits could and should have been estimated in advance, and that any new decision-making system should itself be monitored and reformed if it fails.

The paper’s conclusion is disarmingly simple: presenting screening policy as a straightforward application of evidence-based medicine obscures profound ethical and political choices, and delaying a decision is itself a decision against change — one measured in preventable deaths, avoidable morbidity and widening inequality. As AI begins to exceed human radiologists and pathologists, quantifying future disease risk and optimising screening intervals, governance structures built around static population interventions and decade-long trials will be unable to evaluate products superseded every five years. Who decides, on what basis, and how quickly — the authors argue — are questions that can no longer be left unasked.

Subject of Research: Ethical and policy frameworks for cancer screening decision-making under uncertainty

Article Title: The clinical consequences of excessive caution: rethinking how cancer screening policy is made

Article References: Sasieni, P., & John, S. (2026). The clinical consequences of excessive caution: rethinking how cancer screening policy is made. eClinicalMedicine, Article 104188. https://doi.org/10.1016/j.eclinm.2026.104188

Image Credits: AI Generated

DOI: 10.1016/j.eclinm.2026.104188

Keywords: cancer screening, screening policy, decision-making under uncertainty, health inequalities, prostate cancer screening, bowel cancer screening, multicancer detection tests, artificial intelligence, overdiagnosis, public trust, clinical, consequences